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Abstract: Current research indicates curcumin [diferuloylmethane; a polyphenolic compound isolated
from the rhizomes of the dietary spice turmeric (Curcuma longa)] exerts a beneficial effect on health
which may be partly attributable to its anti-oxidative and anti-inflammatory properties. The aim
of this review is to examine potential mechanisms of the actions of curcumin in both animal and
human studies. Curcumin modulates relevant molecular target pathways to improve glucose and
lipid metabolism, suppress inflammation, stimulate antioxidant enzymes, facilitate insulin signalling
and reduce gut permeability. Curcumin also inhibits Aβ and tau accumulation in animal models
and enhances mitochondria and synaptic function. In conclusion, in high-dose animal studies and
in vitro, curcumin exerts a potential beneficial effect on cardiometabolic disease. However, human
studies are relatively unconvincing. More intervention studies should be conducted with the new
curcumin formulation with improved oral bioavailability.
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1. Introduction
Type 2 diabetes Mellitus (T2DM) is associated with impaired insulin signalling, leading to
hyperglycaemia and micro and macrovascular diseases [1,2]. Insulin resistance is a major contributor to
the pathogenesis of T2DM with secondary pancreatic failure [2,3]. The prevalence of diabetes mellitus
will increase worldwide from 451 million people aged over 18 in 2017 to 693 million people in 2045 [4].
Diabetes is an enormous social, financial and health system burden across the world [4,5]. Lifestyle
modification, including a healthy diet, can lower the risk of T2DM [6]. Dietary polyphenols have been
a major research focus to reduce the risk of T2DM [7–10]. This review aims to present an update on
the effect of curcumin (a polyphenol) on the prevention and treatment of T2DM and cardiovascular
disease (CVD) in animal studies and human studies.
2. Curcumin
Turmeric obtained from the dried Curcumin longa L. (ginger family) is a curry spice. This is
widely consumed as a food ingredient and has long been used for medicinal purposes in China and
Southeast Asia [11–13]. Turmeric is comprised of 3 curcuminoids (curcumin, demethoxycurcumin and
bisdemethoxycurcumin), sugars, proteins, volatile oils (natlantone, tumerone and zingiberone) and
resins [14]. Of the 3 curcuminoids, curcumin is the most active lipophilic polyphenol compound
which is quite stable in the acidic pH of stomach [15,16]. Curcumin is used as a food colorant
(yellow), flavouring, and additive [13]. The chemical structure of pure curcumin (diferuloylmethane) is
1,7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3,5-dione and comprises two ferulic acid residues
joined by a methylene bridge [17]. The structure of curcumin is shown in Figure 1. Commercially available
curcumin contains 77% curcumin, 17% demethoxycurcumin and 3% bisdemethoxycurcumin [13].
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Figure 1. Chemical structure of curcuminoids.
2.1. Curcumin Safety
The Allowable Daily Intake (ADI) value of curcumin is 3 mg/kg body weight [18]. Healthy subjects
consumed curcumins ranging from 0.5 to 12 g/day for 72 h in order to assess the safety of curcumin. Up to
12 g/day of curcumin consumption for 72 h was deemed safe. About 30% subjects showed diarrhoea and
headache, which were not dose-related [19]. Subjects who consumed curcumins at a dose ranging from
0.45 to 3.6 g/day for 1–4 months experienced nausea and diarrhoea. The serum concentrations of alkaline
phosphatase and lactate dehydrogenase were elevated in 3–4 out of 15 patients [20].
A review article investigating the pharmacokinetic interactions of curcumin with conventional
drugs (including cardiovascular drugs, antidepressants, anticoagulants, antibiotics, chemotherapeutic
agents, and antihistamines) showed that curcumin can alter maximum serum concentrations (Cmax)
and area under the curve (AUC) when used with those drugs. Curcumin can inhibit cytochrome
P450 monooxygenases (drug-metabolising enzymes) and P-glycoprotein (an efflux pump from the
ATP-binding cassette (ABC) super family which pumps various xenobiotics (e.g., drugs) out of cells.
Only one clinical trial has demonstrated a significant interaction between curcumin and drugs [21].
2.2. Curcumin Bioavailability
Detectable concentrations of curcumin and its metabolites in both blood and urine were observed
with curcumin ingestion of ≥3.6 g/day in several studies [20,22–25]. The mean plasma concentration
in patients with advanced colorectal cancer refractory to standard chemotherapies who consumed
3.6 g/day of curcumin for up to 4 months was 4.3 ng/mL (i.e., about 0.01 µM/L). The mean plasma
concentrations of curcumin glucuronide and curcumin sulphate were 5.8 and 3.3 ng/mL, respectively,
1 h after administration [20]. The plasma concentrations (mean ± SD) of curcumin for patients with
high-risk or pre-malignant lesions who took 4 g, 6 g and 8 g daily for 3 months were 0.19, 0.20,
and 0.60 µg/mL, respectively [22]. Healthy subjects (n = 6) ingested 10 g of curcumin extract after
hydrolysis of conjugates. The Cmax (mean ± SE) of curcumin conjugates detected as glucuronide
and sulphate were 3.2 ± 0.56 µg/mL. These values were 1000 times higher than those of other study
subjects with lower doses of curcumin (mentioned above [20,22]). The time to reach maximum plasma
concentrations (Tmax) was 4.33 ± 3.2 h [25].
However, other studies [19,22,24–29] showed very low or even undetectable concentrations of
blood curcumin after oral consumption. This may be attributable to chemical instability, low absorption,
rapid metabolism, and enhanced elimination [30]. Animal studies showed that >90% of ingested
curcumin is excreted in the faeces [31]. Microbial metabolites of curcumin have been reported [32–36].
Efforts to enhance curcumin bioavailability have been made, including systemic implants,
curcumin nanoparticles or curcumin with stabilised surfactants [37–42].
Different formulations are available to increase curcumin solubility, circulation, permeability,
bioavailability and resistance to metabolic processes using various materials, such as adjuvants
(piperine), bio-conjugates [turmeric oil, glycine, alanine and epigallocatechin-3-gallate (EGCG)],
lipids (phospholipid), nanoparticles (liposome, micelles, noisome, nanogels, chitosan, gold, silver,
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cyclodextrin, dendrimer, solid lipids), protein (BSA, soy protein isolated) and others (hyaluronic
acid, hydrogel, polymer, PEG-PEI emulsion, polymer encapsulated, beta-lactoglobulin) [26,43,44].
Adjuvant piperine (extracted from black pepper, which suppresses rapid glucuronidation of curcumin
in liver and intestine and then decreases urinary excretion of curcumin), when used with curcumin,
increases free curcumin in tissues leading to increased curcumin bioavailability by ~2000 times [26].
Human interventions showed a favourable effect of the formulation of curcumin with piperine on
anthropometric parameters and lipid profiles [45,46].
Curcumin bioavailability increased 7 to 8 times when curcumin was bio-conjugated with turmeric
oil (BiocurcumaxTM Arjuna Natural Extracts Ltd., Kerala, India) [47]. The formulation of curcumin
bio-conjugates with epigallocatechin-3-gallate (EGCG) [48] and with glycine, alanine and turmeric
oil [49] enhanced curcumin uptake into cells in vitro. The phospholipid-curcumin complex enhanced
bioavailability [50]. A liposome (25–205 nm in diameter)-curcumin complex [43] showed higher
bioavailability than unformulated curcumin.
Noisomes (190–1140 nm in diameter) showed increased curcumin bioavailability [51]. A curcumin
micelle (10–100 nm in diameter) with a nano-sized core and a membrane of hydrophilic polymer
showed enhanced bioavailability [43,52–56]. In a human intervention, nano-micelle curcumin showed
beneficial effects on glucose and lipid profiles in diabetic patients [57]. Moreover, nanogel (10–200 nm
in diameter) [58], chitosan (100–250 nm in diameter) [59,60], gold (200–250 nm in diameter) [61,62],
silver (~15 nm in diameter) [63], cyclodextrin [64], dendrimer (15–150 nm in diameter) [65] and solid
lipids (50–1000 nm in diameter) [66] showed improved solubility and bioavailability of curcumin
in vitro and animal studies.
A curcumin-solid lipid nanoparticle (SLNP), called “Longvida®” (Verdure Sciences, Noblesville,
IN, USA) showed improved bioavailability with a plasma concentration of 0.1–0.2 µM [67]. In a human
intervention, Longvida® showed favourable effects on lipid profiles and memory and mood [68].
Modified curcumin chemical structures (analogues or derivatives of curcumin) have been
developed with enhanced stability, solubility, bioavailability and biological effects. Rapid absorption
(2 h and 57 min) and slow elimination (3 h and 39 min half-life) were shown [69]. Bioavailability was
60% when 32 mg/kg of curcumin analogue (EF-24) was orally administrated to mice [69].
The first curcumin nanoparticle (Theracurmin®, Theravalues Corp., Kioicho Chiyoda-ku, Tokyo, Japan)
showed enhanced bioavailability in healthy subjects [70]. The t1/2 was 9.7 ± 2.1 h for 150 mg and
13.0± 3.3 h for 210 mg and plasma curcumin was still detectable at the 24-h time point [70]. In a human
intervention, Theracurmin® with 90 mg of curcumin twice daily showed favourable effects on memory
and attention [71].
3. Effects of Curcumin on Cardiometabolic Health
A summary of curcumin human intervention studies is shown in Table 1.
3.1. Anti-Oxidative Effects
Oxidative stress is characterised by an imbalance between reactive oxygen species (ROS)
generation and anti-oxidative defence [72]. Hyperglycemia promotes autooxidation of glucose,
glycation of protein and enhanced polyol pathways leading to the increased ROS [73]. Continuous
oxidative stress can cause chronic inflammation which may result in chronic diseases such as T2DM,
CVD and Alzheimer’s disease (AD) [74–77].
The anti-oxidant effect of curcumin as a free radical scavenger appear to be related to its phenolic
O-H and C-H groups [78].
3.1.1. Human Studies
There are fewer than 30 human studies, and most are small and uncontrolled, so the data is
relatively unconvincing. However, it is noted that volunteer characteristics and experimental designs
were rarely the same in different studies.
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Thirty-eight healthy middle-aged subjects (40–60 years old) who consumed a low dose of lipidated
curcumin (80 mg/day) for 4 weeks showed some favourable effects on cardiometabolic health, but no
comparison was made with placebo, so no firm conclusions can be drawn [79].
Yang et al. 2015 [80] conducted a small open uncontrolled study to see if curcumin intake in
subjects with T2DM can lower urinary microalbuminuria excretion. Urinary microalbuminuria was
significantly decreased by 70% (n = 14; p < 0.05) by 500 mg/day of curcumin for 15 days. Moreover,
decreased levels of malondialdehyde (MDA) and increased levels of nuclear factor erythroid 2-related
factor 2 (Nrf2), NAD(P)H: quinone oxidoreductase (NQO1), superoxide dismutase (SOD) were
observed. The levels of lipopolysaccharides (LPS) and caspase 3 decreased. The levels of IκBα and gut
barrier function increased in a before and after comparison. There were no significant differences in
fasting blood glucose, insulin, C-peptide, triglyceride (TG), total cholesterol (TC), HDL-C, low-density
lipoprotein (LDL-C), alanine transaminase (ALT), aspartate transaminase (AST), creatinine and urea
nitrogen (BUN) following 15-day curcumin ingestion compared with the baseline [80].
In a randomised, double-blind, placebo-controlled, crossover study, 62 overweight/obese women
aged over 40–75 years (mean body mass index (BMI) ≥ 34.5 ± 0.8 kg/m2) with C–reactive protein
(CRP) = 8.05 ± 1.33 mg/L who were treated with 2.8 g/day of turmeric (~112 mg/day curcumin)
for 4 weeks showed no changes in oxidative stress (F2-iso-prostanes, oxidised LDL-C), inflammatory
markers (CRP, IL-6, IL-8, IL-10, tumour necrosis factor α (TNFα), IFNγ, IL-1β and IL-12p70), serum
glucose, body weight, percent body fat, systolic blood pressure, augmentation index when compared
with either the placebo or the baseline [81].
3.1.2. Several Possible Mechanisms of Curcumin Anti-Oxidant Activity Have Been Proposed [82–93]
Severe oxidative stress can cause DNA damage and stimulate the DNA repair enzyme poly ADP-ribose
polymerase-1 (PARP-1). Inhibition of PARP-1 reduces tissue injury in oxidative stress-related diseases
(e.g., T2DM and CVD) [94,95]. Curcumin suppressed ROS in islets of streptozotocin-induced diabetic rats
by increasing Cu/Zn SOD and reduced PARP-1 activity, which is a secondary response to inhibition of
ROS-related damage [91].
Curcumin reduced thiobarbituric acid reactive substances (TBARS), lipid peroxidation and MDA,
and increased antioxidant enzyme activities such as SOD, catalase (CAT), glutathione peroxidase (GPx)
and glutathione-S-transferase (GST) in erythrocytes, liver, kidney, heart, pancreas and brain of diabetic
animals [87,88,93] but very high doses were used (e.g., 100 mg/kg).
Curcumin (0–10 µm/L) reduced haemoglobin glycosylation and lipid peroxidation in erythrocytes
under oxidative stress induced by high glucose concentrations [83], and inhibited aldose reductase which in
turn leads to decreased intracellular sorbitol accumulation [84]. Elevated aldose reductase activities cause
increased sorbitol production from glucose, which may increase diabetes complications [85,86]. It is noted
that recent studies indicate aldose reductase inhibitors alone appear to be not effective for prevention of
diabetic complications [96,97].
In alloxan-induced diabetic rats, a glucose-lowering of curcumin (1 g/kg body weight or 0.08 g/kg
body weight) was noted, which led to reduced oxidative stress (decreased TBARS) through the prevention
of glucose influx into the polyol pathway, as well as a decrease in sorbitol dehydrogenase (SDH—converts
sorbitol to fructose) [82].
Curcumin (20 µm/L or 40 µm/L) activated the expression of antioxidant enzymes including
γ-glutamyl-cysteine ligase (GCLM), NQO1 and heme oxygenase 1 (HO-1) in pancreatic β cells and
adipocytes [89,98]. The expression of HO-1 was induced by curcumin through the activation of
Nrf2/antioxidant-responsive element (ARE) pathway in renal epithelial cells [90]. It is noted that Nrf2
is closely associated with oxidative stress-induced inflammation [99].
3.2. Anti-Inflammatory Effects
A meta-analysis of 8 randomised controlled trials (RCTs) [79,100–106] in subjects with a variety of
diseases showed that curcuminoids significantly lowered CRP levels (by a mean 2.2 mg/L) compared
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with a placebo [107]. In a meta-analysis of RCTs [108–113], curcumin significantly reduced TNF-α
(weight mean difference −4.69 pg/mL; 95% CI: −7.10, −2.28; p < 0.001) [114]. In a meta-analysis of
9 RCTs [102,103,106,108,109,111,112,115,116] in subjects with different diseases, curcumin significantly
lowered IL-6 by 0.6 pg/mL (P = 0.01) compared with control [117]. Curcumin supplement (1 g/day,
n = 59) for 8 weeks significantly decreased TNF-α, IL-6, transforming growth factor beta (TGF-β)
and monocyte chemoattractant protein 1 (MCP-1) compared with placebo [112]. In a randomised,
double-blind, crossover trial of 30 obese subjects with BMI ≥ 30, curcumin treatment (1 g/day) for
4 weeks significantly decreased IL-4, IL-1 β and vascular endothelial growth factor (VEGF) without
differences in IL-2, IL-6, IL-8, IL-10, IFN γ, epidermal growth factor (EGF), and MCP-1, compared with
a placebo [111].
Curcumin and Inflammatory Pathways
A mitogen-activated protein kinase (MAPK) regulates embryogenesis, cell differentiation,
proliferation, survival and death [118,119]. The MAPK pathway is comprised of a series of protein
kinases [118–120]. The p38 MAPK pathway is associated with inflammatory responses [121,122].
TNF-α and LPS activate PI 3-kinase in human intestinal microvascular endothelial cells (HIMEC),
and subsequently increase serine/threonine kinase (Akt) phosphorylation for Akt activation. Activated
Akt stimulates MAPK and nuclear factor kappa B (NF-kB) signalling pathways resulting in vascular
cell adhesion molecule (VCAM-1) and MAdCAM-1 expression in the intestine [123,124].
Curcumin suppressed nitric oxide, MCP-1, IL-1β, IL-6, TNF-α, cyclooxygenase-2 (COX-2) and
prostaglandin E2 (PGE2) by suppressing Jun NH2-terminal kinase (JNK), extracellular signal-regulated
kinase1/2 (ERK1/2) and p38MAPK in adipocytes in vitro [125–127] and in other organs [128–131].
Curcumin may reduce diabetes complications related to vascular inflammation. Hyperglycaemic
conditions induce the secretion of proinflammatory cytokines via epigenetic changes, which are mediated by
the opposing actions of histone deacetylases (HDACs) and histone acetylases (HATs) [132,133]. Curcumin
treatment of human monocytic (THP-1) cells under high-glucose conditions increased HDAC2, decreased
HATs activity and expressions of p300 and acetylated CBP/p300 gene expression, consequently leading to
decreased NF-κB transcription activity and proinflammatory cytokine secretion (IL-6, TNF-α) [132].
Oxidative stress and inflammation are contributors to cardiometabolic disease including insulin
resistance, T2DM, CVD and AD. The potent anti-oxidative and anti-inflammatory effects of curcumin
could beneficially influence glucose and lipid homeostasis and endothelial function.
3.3. Glucose Homeostasis
In a randomised double-blind, placebo-controlled study, subjects with non-alcoholic fatty liver
disease (NAFLD) (mean age 46.37 ± 11.57 years; mean BMI 31.35 ± 5.67 kg/m2; n = 77) consumed
500 mg/day of an amorphous dispersion curcumin formulation (equivalent to 70 mg curcumin)
for 8 weeks. Curcumin consumption significantly reduced glucose, glycated haemoglobin (HbA1c),
TC, LDL, TG, liver fat content, BMI, aspartate aminotransferase (AST), alanine aminotransferase
(ALT) compared with the placebo [134]. All the changes seen may be due to the loss of weight seen
in the curcumin group (over 2 kg difference over 8 weeks), which may be caused by nausea and
anorexia, which caused 3 dropouts as well. Ultrasound is not a reliable method amount of liver fat.
Large changes in HbA1c were seen in both groups. In a randomised double-blind, placebo-controlled
trial of 100 overweight/obese subjects with T2DM (average age: 54.72 ± 8.34 years; BMI ≥ 24.0;
curcuminoids (300 mg/day; n = 50) supplementation for 12 weeks significantly reduced fasting glucose,
HbA1c and homeostasis model assessment insulin resistance (HOMA-IR) with decreased levels of
serum free fatty acids (FFAs) and TG, and increased lipoprotein lipase (LPL) activity compared with
a placebo. However, levels of TC, LDL- C, HDL- C, Apo A-I or Apo B did not differ. Anthropometric
variables such as body weight and waist and hip circumferences were also not altered on curcuminoids
supplementation compared with a placebo [135].
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In a randomised, double-blind, placebo-controlled trial of prediabetic subjects (n = 237), curcumin
treatment (a total of 6 capsules/day—250 mg curcuminoid/capsule) significantly decreased HbA1c,
fasting glucose and OGTT at 3, 6, and 9 months compared with a placebo (p < 0.01) and reduced
the diagnosis of T2DM from 16.9% to 0%. At 3 months, curcumin treatment significantly increased
HOMA-β (p < 0.01) compared with a placebo. At 9 months, C-peptide and insulin were significantly
attenuated with curcumin treatment compared with a placebo (p < 0.05). Moreover, curcumin treatment
significantly reduced HOMA-IR at 6 and 9 months and elevated adiponectin at 9 months compared
with a placebo [136]. Curcumin treatment significantly decreased body weight by 6.2 kg at 9 months
compared with a placebo which could account for all of the observations on glucose and HbA1c.
AST, ALT, creatinine, bone mineral density and waist circumference were not altered with curcumin
treatment compared with a placebo. This clinical study supports the preventive effect of curcumin on
the development of T2DM in individuals with prediabetes [136].
Adiponectin acts as an insulin sensitiser to suppress hepatic gluconeogenesis via AMP-activated
protein kinase (AMPK)-dependent and -independent pathways. It stimulates fatty acid oxidation
predominantly in skeletal muscle to activate glucose uptake [137]. Increased adiponectin levels were
observed with curcumin supplementation (1 g/day) for 6 weeks in subjects with metabolic syndrome
compared with a curcumin-phospholipid complex group or a placebo group, whereas no differences
in BMI, body weight, waist circumference, fasting blood glucose, fat (%) were observed compared
with a curcumin-phospholipid complex group or a placebo group [138].
In a randomised double-blind, placebo-controlled design, subjects with T2DM (mean age 59± 10.6 years;
n = 107) were treated with 250 mg of curcumin (3 times/day) for 6 months. Curcumin treatment increased
adiponectin and decreased leptin levels compared with the placebo. Pulse wave velocity (PWV), HOMA-IR,
TG, uric acid, abdominal obesity (visceral fat and total body fat) were significantly reduced with curcumin
treatment compare with the placebo [139].
In a randomised crossover study, 11 healthy subjects supplemented with turmeric (2.8 g/day) for
4 weeks showed no changes in fasting plasma glucose, TC and TG compared with the control (water
only) [140]. In a crossover design, 14 healthy subjects who consumed 6 g of encapsulated turmeric with
a standard 75 g oral glucose tolerance test (OGTT) showed increased insulin responses with no difference in
postprandial glucose responses compared with the reference OGTT with placebo capsules [141].
The effect of curcumin on glucose control is inconclusive, as five RCTs [57,134–136,139] showed
positive effects and ten RCTs [80,81,108,138,140,142–146] showed no effect.
Potential Mechanisms of Curcumin
On the other hand, in vitro and high-dose animal studies supports the glucose lowering effects
of curcumin. A high-fat diet (HFD) was given to male Wistar rats (7 weeks of age) for 6 weeks,
and then diabetes was induced by streptozotocin injection (30 mg/kg body weight). Three different
concentrations of curcumin (50, 150, or 250 mg/kg body weight) were used for 7 weeks. Curcumin
(especially, 150 mg/kg body weight) significantly improved glucose and insulin tolerance compared
with normal control rats [147]. In addition, in the in vitro study, L6 myotube cells were treated with
different concentrations of curcumin (5, 10, 20, or 40 µm/L) in the presence of palmitate (0.25 mM/L).
The 2-deoxy-[3H] D-glucose uptake was enhanced by curcumin in a dose dependent manner and
glucose transporter 4 (GLUT4) protein expression increased on the cell membrane of L6 myotubes [147].
C57BL/KsJ-db/db mice and their age-matched lean non-diabetic db/+ mice were fed a diet with
curcumin or without curcumin (0.02%, wt/wt) for 6 weeks. In db/db mice, curcumin decreased glucose
and HbA1c, improved HOMA-IR and glucose tolerance as assessed by intraperitoneal glucose tolerance
test (IPGTT) and increased insulin levels. Curcumin did not alter glucose tolerance and insulin levels
in db/+ mice. Curcumin increased hepatic glucokinase (GK) activity and suppressed the elevation of
hepatic gluconeogenic enzyme activities, glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate
carboxykinase (PEPCK) in db/db mice. Curcumin increased glycogen storage in the liver in the db/db
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mice, while curcumin did not alter hepatic GK, P6Pase, PEPCK and glycogen content in non-diabetic
db/+mice. These findings indicate that curcumin can lower glucose levels in db/db mice [93].
AMPK plays a key role in glucose and fatty acid metabolism [148]. Its roles in activation of catabolic
processes aimed at ATP production (e.g., glucose uptake, glycolysis, fatty acid uptake, and β-oxidation) and
inhibition of anabolic pathways (e.g., synthesis of glycogen, proteins, fatty acids, and cholesterol) have been
well documented [149].
Curcumin treatment (10–20 µm/L, 10 µm/L, or 15, 30 and 60 mg/kg body weight) elevated insulin
sensitivity by increasing insulin receptor substrate-1 (IRS1) protein, Akt, extracellular signal-regulated
protein kinases 1 and 2 (ERK1/2), p38 MAPK, and AMPK in C2C12 skeletal muscle cells [150],
L6 myotube cells [151] and in the liver of fructose-fed rats [152]. Curcumin (10 µm/L) also increased
insulin sensitivity in skeletal muscle by promoting oxidation of glucose and fatty acid mediated in
part through serine–threonine liver kinase B1 (LKB1)-AMPK pathway [147].
Curcumin (10 µm/L) improved insulin secretion by activating phosphoinositide 3–kinase (PI3K)
or Akt, inhibiting forkhead box protein O1 (FoxO1), alleviating endoplasmic reticulum (ER) stress and
enhancing mitochondrial survival from lipotoxicity in palmitate-treated MIN 6 pancreatic β cells [153].
Curcumin (2–10 µm/L) lowered glucose by stimulating β-cell function by activating the volume-
regulated anion channel enhancing insulin secretion in rat pancreatic β-cells [154]. Curcumin (1–100 pmol/L)
also enhanced pancreatic β-cell function acting as a cyclic nucleotide phosphodiesterase (PDE) inhibitor.
Curcumin treatment downregulated expression of PDEs (enzymes which convert cyclic AMP and cyclic
GMP into 5′ AMP and 5′-GMP), leading to elevated intracellular cAMP levels with improved insulin release
from pancreatic β-cells [155].
In high-fat diet-induced obese and leptin-deficient ob/ob male C57BL/6J mice, the improved glucose
control following curcumin treatment (3% dietary curcumin) was associated with anti- inflammatory
effects of curcumin by decreasing macrophage infiltration into adipocytes, and by increasing adiponectin
production in white adipocytes, by decreasing ER stress (elevated ER stress in adipocytes and hepatocytes is
related to obesity) and perigonadal fat expression of Sirtuin 1 (SIRT1), heat shock proteins (HSP70), HSP90
and Foxo1 and decreasing NF-κB activity in liver [156]. SIRT1 is a regulator of adiponectin transcription
through the activation of Foxo1 and Foxo1 and C/EBPalpha interaction in adipose tissue [157]. SIRT1 plays
a role in glucose homeostasis, inducing hepatic glucose production through the deacetylation of PGC-1α
and by repressing peroxisome proliferator-activated receptor gamma (PPAR γ) [158,159].
Curcumin supplementation (15, 30 and 60 mg/kg) increased IRS1 resulting in improved insulin
sensitivity via increased expression of PPAR γ and Akt and ERK1/2 in liver of fructose-fed rats [152].
3.4. Lipid Homeostasis
Seven RCTs [45,68,100,134,135,139,143] showed positive lipid profile changes, while ten
RCTs [57,79–81,108,140,142,145,160,161] showed no effect. Therefore, evidence that curcumin is
beneficial is still lacking.
A further meta-analysis of RCTs also showed no effect of curcumin on lipid profiles [162].
According to a 2017 position paper from an International Lipid Expert Panel, the lipid lowering
effect of curcumin in human intervention studies is inconsistent, but several recent interventions report
favourable effects on lipid profiles [134,143,146,163,164].
In a randomised double-blind, placebo-controlled parallel study of 117 subjects with metabolic
syndrome (aged 25–75 years), supplementation of 1000 mg/day of curcuminoids and piperine
(bioperine® Sami Labs LTD, Bangalore, Karnataka, India) (100:1 ratio combination) for 8 weeks
significantly lowered LDL-C, non-HDL-C, TC, TG and lipoprotein(a) [Lp(a)] and increased HDL-C,
compared with the placebo. The lipid changes were significant after adjustment for baseline of BMI
and lipids. No change in small dense LDL (sdLDL) was observed [163].
In a randomised placebo-controlled study of 87 subjects with non-alcoholic fatty liver disease,
1000 mg/day of curcumin plus dietary and lifestyle intervention for 8 weeks significantly decreased
TC, non-HDL-C, LDL-C, TG and uric acid compared with placebo. No differences in HbA1c, fasting
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glucose, insulin, HOMA-IR, HOMA-β, quantitative insulin sensitivity check index (QUICKI) were
seen compared with placebo [146].
In a randomised, double-blind, placebo-controlled trial in 70 subjects with T2DM, nano-curcumin
(80 mg/day) for 3 months significantly reduced HbA1C, fasting blood glucose, TG, and BMI before
and after the treatment [57].
In a randomised, double-blind, placebo-controlled trial, 33 subjects aged 40–60 years with
metabolic syndrome (mean BMI: 30.06 ± 4.12 kg/m2) were supplemented with 630 mg of curcumin
extract (95% curcuminoids, including curcumin, demethoxycurcumin, and bisdemethoxycurcumin)
three times per day for 12 weeks. In comparison with the placebo, LDL-C significantly decreased
with curcumin supplementation with no changes in weight, BMI, fasting glucose, HbA1C, TG, TC,
very low-density lipoprotein (VLDL), HDL-C, Non-HDL-C and T-Chol/HDL-C ratio [143].
In a randomised, double-blind, placebo-controlled, parallel study investigating the effect of
curcumin (400 mg/day as Longvida®) on cognition, mood and biomarkers in 60 elderly subjects (mean
age: 68.5 years) for 4 weeks significantly lowered TC and LDL-C with the significant improvement
memory and mood compared with the placebo [68].
In a randomised double-blind, placebo-controlled crossover trial, 30 subjects aged 18–65 years who
were not taking lipid-lowering agent, as well as who had any conditions including BMI ≥ 30 kg/m2 or
2 risk factors (except for T2DM) for coronary heart disease (CHD) or ≥ 2 risk factors (except for T2DM)
for CHD and 130 mg/dL < LDL-C < 160 mg/dL, were supplemented with curcuminoids (1 g/day) for
30 days. Curcuminoids supplementation decreased TG levels with no differences, LDL-C, HDL-C and
CRP. Anthropometric variables such as body weight, BMI, waist circumference, arm circumference, and fat
percentage also were not altered with curcuminoids supplementation compared with the placebo [100].
In a randomised double-blind, controlled trial, subjects with acute coronary syndrome, curcumin
ingestion (45–180 mg/day) for 1 year showed no changes in lipids [145]. In a randomised, double-blind
study of 36 elderly subjects (mean age: 73.4 ± 8.8 years), either 4 g/day or 1 g/day of curcumin
supplementation did not significantly alter TG, LDL-C and HDL-C over 1 month or 6 months
compared with a control [160]. In a double-blind, randomised, placebo-controlled, 2 × 2 factorial
trial, 70 hypercholesterolemia subjects (mean fasting TC: 6.57 ± 0.13 mM/L) were randomised to
either curcumin (200 mg/day: Meriva ® Indena) plus phytosterols (2 g/day; n = 17) or curcumin
(200 mg/day; n = 18) or phytosterols (2 g/day; n = 17) or placebo (n = 18) for 4 weeks. Phytosterol
group and curcumin plus phytosterol group showed significant reductions in TC, LDL-C and TC:
HDL-C compared with the baseline, whereas the curcumin group did not significantly alter TC and
LDL-C. HDL-C and TG were not altered in any group [161].
Potential Mechanisms of Actions of Curcumin on Lipids
In vitro [165,166] and animal studies [93,152,167–174] showed improved lipid profiles following
curcumin treatment.
In the human hepatoma cell line (HepG2), a potential hypocholesterolemic effect of curcumin
(0.02% wt/wt) was observed with elevated gene expressions of the LDL-receptor. Curcumin (80 mg/kg)
has been shown to downregulate fatty acid synthase (FAS—related to increased plasma lipid levels)
and increase skeletal muscle LPL [93,167].
Statins are lipid-lowering medications known as HMG-CoA reductase inhibitors. Curcumin
(0.02% wt/wt) has been shown to decrease HMG-CoA reductase activity leading to reduced plasma
and hepatic cholesterol levels [93,175].
In animals fed a high-fat diet, curcumin treatment (0.05 g/100 g diet) has been shown to decrease
hepatic acyl-CoA: cholesterol acyltransferase (ACAT) which may decrease intestinal cholesterol uptake
and transport in the intestine [93,172].
Curcumin treatment (0.5% dietary curcumin or 0.1% wt/wt) also has been shown to increase
hepatic cholesterol 7 α-hydroxylase (CYP7A) which is a rate-limiting enzyme responsible for the
biosynthesis of bile acid from cholesterol [171,176,177].
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Activated AMPK suppresses fatty acid synthesis in the liver by suppressing liver X receptor α (LXR α)
-dependent sterol regulatory element-binding protein [(SREBP)-1c—a major gene transcription factor for
hepatic lipogenesis] [178,179]. Elevated hepatic lipogenesis is associated with insulin resistance [178,179].
In the liver, curcumin (4 g/kg diet or 0.02% wt/wt) suppressed SREBP1c, and the carbohydrate response
element-binding protein (ChREBP) [98] and upregulated LXR α to decrease TG levels [175].
A cholesterol transporter, ATP-binding cassette A1 (ABCA1) transporter acts as cholesterol efflux
regulatory protein. Curcumin (5, 10 and 20 µg/mL) has been shown to promote cholesterol efflux from
adipocytes via PPAR γ-LXR α-ABCA1 pathway (activation of PPAR γ, LXR α and ABCA1) [180].
Ezetimibe, known as a Niemann-Pick C1 Like 1 (NPC1L1) inhibitor, is a cholesterol-lowering
medication which reduces cholesterol absorption in the small intestine. Curcumin treatment (50 µm/L
or 25–100 µm/L) in Caco-2 cells inhibited NPC1L1 through the inhibition of SREBP-2 [181,182].
Curcumin treatment (100 or 400 mg/kg body weight) has been shown to decrease serum TG and
fetuin-A (α2-Heremans-Schmid glycoprotein) levels in liver of rats fed a high-fat diet [174]. Fetuin-A
produced in the liver is associated with insulin resistance and fatty liver [183,184].
3.5. Weight Control
In a systematic review [185] of 8 RCTs [46,81,100,134,135,139,143,186], 3 studies [46,134,139] showed
a favourable effect on weight control while 5 studies [81,100,135,143,186] showed no effects [185]. Moreover,
RCTs [136,138,142] included in this review showed no effect, and RCTs [45,57] showed a positive effect on
weight control. Given the findings from limited numbers of RCTs [45,46,57,81,100,134–136,138,139,142,143,186],
curcumin at usual doses is unlikely to contribute to weight control.
In a randomised double-blind, placebo-controlled trial of subjects with T2DM, curcuminoids
(1000 mg/day combined with piperine 10 mg/day) for 12 weeks significantly decreased body weight,
BMI, TC and Lp(a) and increased HDL-C compared with a placebo. However, curcumin did not alter
TG and LDL-C compared with the placebo [45].
In a randomised parallel trial, overweight subjects with metabolic syndrome (mean BMI 25–29.9 kg/m2;
mean age 39.1± 16.8 years; n = 44) who adhered to a diet plus lifestyle intervention for 30 days (adherence
rate > 80% and a weight loss < 2%) underwent either curcumin treatment (800 mg twice per day; n = 22)
plus lifestyle intervention or phosphatidylserine plus lifestyle intervention for 4 weeks. Significant reductions
in body weight, body fat, waistline and BMI were observed with curcumin treatment compared with the
phosphatidylserine group [46].
On the other hand, in a randomised, double-blind, placebo-controlled, crossover study, obese
subjects (mean BMI: 33.95 ± 3.81) who were treated with curcuminoids (1 g/day) for 30 days showed
no differences in BMI and weight compared with the placebo [186].
Potential Mechanisms
Curcumin (80 mg/kg diet or 500 mg/kg diet or 1.5 g/kg diet or 4 g/kg diet or HFD containing
0.15% curcumin) led to reduced body weight and/or body fat in HFD-fed mice [98,156,167–169].
Curcumin (5, 10, 20 µm/L) has been documented to decrease palmitate-induced insulin resistance in
3T3-L1 adipocytes [126]. Curcumin (0-100 µm/L) has also been shown to inhibit glucose transport
in 3T3-L1 adipocytes [187–189]. Curcumin (10, 25, 50, and 75 µm/L) induced insulin resistance by
suppressing insulin-stimulated protein kinase B (Akt)/GLUT4 signalling with activation of autophagy
in 3T3-L1 adipocytes [189].
Stearoyl-coenzyme A desaturase 1 (SCD-1) is a rate enzyme in the synthesis of unsaturated fatty
acids [190]. Upregulation of SCD-1 may be associated with obesity, insulin resistance and atherosclerosis [191].
Curcumin (80 mg/kg) treatment for 12 weeks in HFD-induced obese mice has been shown to downregulate
the expression of SCD-1 in brown adipose tissue and white adipose tissue [167].
The browning effect of white fat by curcumin has been reported in several studies [192–194]. Brown
adipose tissues generate heat from fat through uncoupling proteins (UCP1) present in the mitochondrial
inner membrane. Brown adipose tissues are known to play a critical role in non-shivering thermogenesis
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against cold [195]. Brown adipose tissues can be derived from white adipose tissues with stimuli including
cold, and adrenergic compounds [196–201]. Thermogenic gene expression (e.g., UCP1, PGC1 α, Prdm16,
Dio2, PPAR γ, Cidea, Elovl3, Nrf1, mtTfa, and ATPsyn) and mitochondrial biogenesis are increased with
the browning of white adipose tissue. Curcumin (80 mg/kg) treatment for 12 weeks in HFD-induced
obese mice has been shown to upregulate mRNA expressions of UCP1 in brown adipose tissue and white
adipose tissue [167].
Norepinephrine binding to beta 3 adrenoreceptors (β3AR) present in white adipose tissues are
known to exert a key role in the browning of white adipose tissues [202]. Curcumin treatment (50 or
100 mg/kg) in C57BL/6J mice elevated plasma norepinephrine levels and upregulated β3AR gene
expression in inguinal white adipose tissues and induced browning with the decreased body weight
and fat accumulation compared with control mice [192].
Curcumin (1–20 µm/L) induced fat browning through AMPK-mediated pathway in 3T3-L1 and
primary white adipocytes [193]. Curcumin (40 and 80 mg/kg) decreased white and brown adipocyte
diameters and insulin resistance caused by a high fat diet via inhibition of SREBPs [167].
Curcumin (25 µm/L) also exerts an anti-adipogenic effect via stimulating the Wnt/β-catenin signalling
pathway with stimulation of downstream targets such as c-Myc and cyclin D1, and by inhibiting
glycogen synthase kinase-3 beta (GSK-3β) and Axin, consequently resulting in downregulation of JNK
phosphorylation. Curcumin treatment in 3T3-L1 cells suppressed adipocyte differentiation by suppressing
adipogenic transcription factors (C/EBPα, PPAR γ and C/EBPα) and their downstream factors (SREBP-1
and FASN) [203].
3.6. Gut Microbiome Changes
Lifestyle including dietary pattern, exercise, sleep and environmental factors can affect the gut
microbiota [204–207]. Gut microbial dysbiosis is associated with obesity, metabolic syndrome, diabetes,
CVD and neurodegenerative diseases [208–212].
Very limited studies showed that curcumin favourably modified the gut microbiota
composition [213–217]. HFD-fed rats administrated with curcumin showed enhanced diversity of
bacterial strains. A HFD increased metabolic endotoxemia and gut inflammation, which decreased
with curcumin administration (200 mg/kg) [217].
Gut microbial dysbiosis appears to increase gut permeability, leading to an increased inflammatory
response [218]. A positive association between a high-fructose diet and/or a high-fat diet and increased
gut permeability has been reported [217–220].
In vitro, LPS increases IL-1 β which can activate p38 MAP kinases and subsequently myosin light
chain kinases (MLCK). The phosphorylation of myosin light chains can increase gut permeability.
Curcumin treatment decreased LPS-induced release of IL-1 β from intestinal epithelial cells and
intestinal macrophages. Curcumin (5 µm/L) also suppressed p38 MAPK activation by IL-1 β and
myosin light chain kinase in intestinal epithelial cells [221].
Animal studies [222–225] also showed improvement of gut permeability with the curcumin treatment.
A mouse model fed a Western diet for 16 weeks exhibited elevated intestinal permeability [224]. Curcumin
(5 µm/L) decreased plasma LPS levels and increased intestinal alkaline phosphatase activity and tight
junction protein expressions (ZO-1 and claudin-1) [224].
Mitogen-activated protein kinase phosphatase 1 (MKP-1) exerts an essential role in dephosphorylating
MAPK and inactivating ERK, JNK and p38 in response to stress [226,227]. Curcumin (100 mg/kg) decreased
the impairment of intestinal mucosa barrier by methotrexate in rats through the activation of MKP-1 and
suppression of p38 and NF-kB [222]. Therefore, curcumin appears to reduce gut permeability induced by
external dietary factors (e.g., a western diet) or exogenous injury by altering signal pathways, consequently
leading to the prevention of a chronic inflammatory state [228].
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3.7. Endothelial Function
Curcumin has a protective effect on endothelial dysfunction [108,229–234]. The improved endothelial
function on curcumin treatment is attributable to several mechanisms including hypoglycaemic [229] and
hypolipidemic effects [229], and anti-inflammatory [235,236], anti-oxidant activities [229,230,232,233].
In a randomised, controlled, double-blind parallel study of 59 healthy subjects, curcumin supplementation
(200 mg/day) for 8 weeks improved endothelial function as assessed by flow-mediated dilation (FMD)
compared with placebo [237]. Sixty-seven subjects with T2DM who ingested NCB-02 (300 mg/day
of curcumin) for 8 weeks showed significantly enhanced endothelial function (measured using digital
plethysmography) with lower levels of MDA, ET-1, IL-6 and TNF-α compared with the baseline, but statistical
comparison was not made with placebo. These beneficial effects of curcumin (NCB-02) on endothelial function
through anti-inflammatory and antioxidant actions are comparable to those of atorvastatin (10 mg/day).
However, in comparison with the baseline, NCB-02 did not significantly alter fasting glucose, HbA1c, TC,
LDL-C HDL-C and TG, while atorvastatin significantly lowered TC, LDL-C and TG [108].
In a double-blind, parallel, randomised study of healthy middle-aged and older adults (45–74 years)
curcumin supplementation (2000 mg/day Longvida®) for 12 weeks improved resistance artery endothelial
function with enhanced forearm blood flow to brachial artery infusion of acetylcholine (FBFACh) when
infused with vitamin C following curcumin compared with baseline (but not placebo in any variable).
Curcumin also increased brachial artery FMD. Curcumin reversed the decrease in FBFACh from the nitric
oxide synthase inhibitor, NG monomethyl-L-arginine. Curcumin did not alter the levels of adiponectin,
leptin, insulin, HOMA-IR, oxidised LDL-C, total antioxidant status, GPx, IL-6, TNF-α, cortisol, epinephrine,
norepinephrine and endothelin-1 (ET-1) compared with baseline or placebo [144].
Curcumin treatment (30 and 300 mg/kg) in streptozotocin-induced diabetic rats reduced vascular
superoxide anion (O2 −) production and inhibited vascular protein kinase C (PKC-bII) resulting in
improved endothelial function [232]. Vascular endothelial cell damage resulting from oxidative stress
can be protected by curcumin treatment via autophagy activation. In human umbilical vein endothelial cells
(HUVECs) under the condition of oxidative stress induced by hydrogen peroxide H2O2, curcumin treatment
(1, 5 and 10 µm/L) increased microtubule-associated protein 1 light chain 3-II (LC3-II—an autophagosomal
marker) in a dose-dependent manner.
Curcumin (1, 5 and 10 µm/L) protects vascular endothelial cells through autophagic process
by inhibiting the PtdIns3K-AKT-mTOR signalling pathway and FOXO1 (a mediator of autophagy)
nuclear localisation and FOXO1-related proteins [230].
Curcumin (0.25–2.5 µm/L) also protects vascular endothelial cells by trapping methylglyoxal (MGO—
a major reactive dicarbonyl compound) and reducing Nε-(carboxymethyl) lysine (CML) formation in
HUVECs. This protective effect is responsible for directly trapping MGO by curcumin [231].
Curcumin treatment (2.5, 5, 10 and 20 µm/L) of HUVECs and lymphocytes (Jurkat cells) exposed
to either high glucose or advanced glycation end products (AGEs) restored transmembrane potential.
Curcumin treatment decreased membrane fluidity in AGE-exposed Jurkat cells or glucose-exposed
Jurkat cells. In addition, curcumin treatment inhibited MCP-1 release from Jurkat cells and HUVECs
exposed to AGEs or glucose showing an anti-inflammatory action [238].
Lectin-like oxidised LDL receptor-1 (LOX-1), a receptor expressed in vascular cells for oxidised LDL,
contributes to the pathogenesis of diabetic atherosclerosis [239]. As the glucose concentrations (5.6 to
30 mM/L) increased, expressions of LOX-1 gene and protein increase in human monocyte-derived
macrophage (MDMs) [236]. The high concentration of glucose led to increased formation of foam cells
in macrophage [240]. In a vitro study curcumin (10 µm/L) via activated protein-1 (AP-1—a transcription
factor [241]) inhibition appeared to suppress the formation of macrophage-derived foam cells stimulated
with high glucose levels via the LOX-1–dependent pathway [236]. Curcumin (5 µm/L) can prevent
macrophages via LXRα dependent AMPK-signalling pathways in the human THP-1 cell line from being
transformed into foam cells leading to the prevention of atherosclerosis [165].
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Table 1. Summary of curcumin human intervention studies.
Dose Design Subjects Period Effects No Effects Ref
1 g/day of curcuminoids (curcumin C3
Complex®Sami Labs LTD, Bangalore,





100 subjects with T2DM aged
18–65 years 12 weeks
↓ body weight, ↓ BMI, ↓ TC,
↓ Lp(a), ↑ HDL-C compared
with the placebo
TG, LDL-C compared with
the placebo Panahi et al. 2017 [45]
800 mg × 2/day of curcumin-based
product (enteric-coated and containing
800 mg/dose/die of 95% curcumin
complexed with 20% phosphatidylserine
and blended with 8 mg/dose/die of
piperine) + lifestyle intervention, or 400
mg × 2 day of phosphatidylserine +
lifestyle intervention
randomised parallel
44 overweight subjects with
metabolic syndrome (mean
BMI 25–29.9 kg/m2; mean age
39.1 ± 16.8 years)
4 weeks
↓ body weight, ↓ body fat,
↓ waistline, ↓ BMI compared
with the
phosphatidylserine group
Di Pierro et al. 2015 [46]
80 mg/day of nano- micelle curcumin
(SinaCurcumin®Exir Nano Sina Co.,




70 subjects with T2DM aged
over 18 years 3 months
↓ HbA1C, ↓ fasting blood
glucose, ↓ BMI compared with
the placebo
TC, LDL-C, HDL-C compared
with the placebo Rahimi et al. 2016 [57]
400 mg /day of Longvida®






60 elderly subjects (mean age:
68.5 years) 4 weeks
↓ TC, ↓ LDL-C,
↑memory, ↑mood
compared with the placebo
Cox et al. 2015 [68]
80 mg/day of lipidated curcumin
(Longvida®)
38 healthy middle-aged
subjects (40–60 years old) 4 weeks
TC, LDL, HDL-C, CRP, TG,
salivary amylase, salivary
radical scavenging capacities,
catalase, beta amyloid protein,
sICAM, myeloperoxidase,
nitric oxide, ALT
Disilvestro et al. 2012 [79]
500 mg/day of curcumin open uncontrolled 14 subjects with T2DM 15 days
fasting glucose, insulin,
C-peptide, TG, TC, HDL-C,
LDL-C, ALT, AST, BUN
Yang et al. 2015 [80]







aged over 40–75 years [mean
(BMI) ≥ 34.5 ± 0.8 kg/m2]
with CRP = 8.05 ± 1.33 mg/L
4 weeks
F2-iso-prostanes, oxidised
LDL-C, CRP, IL-6, IL-8, IL-10,
TNFα, IFNγ, IL-1β, IL-12p70,
glucose, body weight,
percent body fat, SBP,
augmentation index
Nieman et al. 2012 [81]
1 g/day of curcuminoids (500 mg





30 subjects aged 18–65 years
who were not taking
lipid-lowering agent, as well
as who had any conditions
including BMI ≥ 30 kg/m2
or 2 risk factors (except for
T2DM) for CHD or ≥ 2 risk
factors (except for T2DM) for
CHD and 130 mg/dL <
LDL-C <160 mg/dL
30 days ↓ TG compared withthe placebo




Mohammadi et al. 2013 [100]
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Table 1. Cont.
Dose Design Subjects Period Effects No Effects Ref




67 subjects with T2DM aged
21–80 years 8 weeks
fasting glucose, HbA1c, TC,
LDL-C, HDL-C and TG
endothelial function, MDA,
ET-1, IL-6, TNF-α
Usharani et al. 2008 [108]
1 g/day of curcuminoids (500 mg




30 obese subjects with BMI≥ 30 4 weeks ↓ IL-4, ↓ IL-1 β, ↓ VEGFcompared with the placebo
IL-2, IL-6, IL-8, IL-10, IFN γ,
EGF, MCP-1 Ganjali et al. 2014 [111]
1 g/day of curcumin 117 subjects withmetabolic syndrome 8 weeks
↓ TNF-α, ↓ IL-6, ↓ TGF-β,
↓MCP-1 compared
with placebo
Panahi et al. 2016 [112]
500 mg/day of an amorphous dispersion





77 subjects with NAFLD
(mean age 46.37± 11.57 years;
mean BMI 31.35± 5.67 kg/m2)
8 weeks
↓ glucose, ↓ HbA1c, ↓ TC, ↓
LDL, ↓ TG, ↓ liver fat, ↓ BMI,
↓ AST, ↓ ALT compared with
the placebo
Rahmani et al. 2016 [134]





with T2DM (average age:
54.72± 8.34 years; BMI≥ 24.0
12 weeks
↓ fasting glucose, ↓ HbA1c, ↓
HOMA-IR, ↓ FFAs, ↓ TG, ↑
LPL compared with a placebo
TC, LDL- C, HDL- C, Apo A-I
or Apo B, body weight, waist
and hip circumferences
Na et al. 2013 [135]




237 prediabetic subjects 3, 6, 9 months
↓ HbA1c, ↓ fasting glucose, ↓
OGTT at 3, 6, and 9 months, ↓
diagnosis of T2DM, ↑
HOMA-β at 6 & 9 months, ↑
adiponectin at 9 months, ↓
C-peptide at 9 months, ↓
insulin at 9 months, ↓ body
weight at 9 months compared
with the placebo
AST, ALT, creatinine, bone
mineral density,
waist circumference
Chuengsamarn et al. 2012 [136]
1 g/day of phospholipidated curcumin
(n = 40) equivalent to 200 mg/day of pure
curcumin, or 1 g/day of unformulated




120 subjects with metabolic
syndrome aged 18–65 years 6 weeks




complex group or the
placebo group
BMI, body weight, waist
circumference, fasting blood




Salahshooh et al. 2017 [138]




subjects with T2DM (mean
age 59 ± 10.6 years; n = 107 6 months
↑ adiponectin, ↓ leptin, ↓ PWV,
↓ HOMA-IR, ↓ TG, ↓ uric acid,
↓ visceral fat, ↓ total body fat
compared with the placebo
Chuengsamarn et al. 2014 [139]
2.8 g/day of turmeric randomisedcrossover
11 healthy subjects aged
21–38 years 4 weeks fasting glucose, TC, TG Tang et al. 2008 [140]
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Table 1. Cont.
Dose Design Subjects Period Effects No Effects Ref
6 g of curcuma C. longa (turmeric) crossover, acute
14 healthy subjects (mean age:
29 ± 1 years, BMI: 23.9 ±
2.7 kg/m2)
↑ insulin responses compared
with the placebo postprandial glucose responses Wickenberg et al. 2010 [141]




nondiabetic obese subjects 12 weeks
BDNF, body weight, BMI, fat,
glucose, TC, LDL, TG, HDL-C,
VLDL, uric acid, oxLDL,
protein carbonyls
Franco-Robles et al. 2014 [142]




33 subjects aged over
40–60 years with metabolic
syndrome (mean BMI:
30.06 ± 4.12 kg/m2)
12 weeks ↓ LDL-Ccompared with the placebo
weight, BMI, fasting glucose,
HbA1C, TG, TC, VLDL,
HDL-C, Non-HDL-C and
T-Chol/HDL-C ratio
Yang et al. 2014 [143]




39 healthy middle-aged and
older adults (45–74 years) 12 weeks Nil compared with placebo
adiponectin, leptin, insulin,
HOMA-IR, oxidised LDL-C,
total antioxidant status, GPx,
IL-6, TNF-α, cortisol, ET-1
FMD resistance artery
endothelial function (FBFACh)
Santos-Parker et al. 2017 [144]




75 subjects with acute
coronary syndrome 1 year
TC, LDL-C, HDL-C, TG,
fasting glucose, 2-hour glucose Alwi et al. 2008 [145]
1000 mg/day of curcumin + dietary and
lifestyle intervention
Randomised,
placebo-controlled 87 subjects with NAFLD 8 weeks
↓ TC, ↓ non–HDL-C, ↓ LDL-C,
↓ TG ↓ uric acid compared
with the placebo.




compared with the placebo.
insulin, HOMA-IR, HOMA-β.
QUICKI within the group.
Panahi et al. 2016 [146]




36 elderly subjects (mean age:
73.4 ± 8.8 years)
over 1 month
or 6 months TG, LDL-C, HDL-C Baum et al. 2007 [160]
200 mg/day of curcumin (Meriva ®, Indena
SpA, Viale Ortles, Milan, Italy) + 2 g/day of
phytosterols (n = 17), or 200 mg/day of
curcumin (n = 18), or 2 g/day of




2 × 2 factorial trial
70 hypercholesterolemia
subjects (mean fasting TC:
6.57 ± 0.13 mM/L) aged
18–70 years
4 weeks
↓ TC, ↓LDL-C and↓ TC:
HDL-C within phytosterol
group and within curcumin
plus phytosterol group. No
change with curcumin alone
Ferguson et al. 2018 [161]
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Table 1. Cont.
Dose Design Subjects Period Effects No Effects Ref
1000 mg/day of curcuminoids and piperine





117 subjects with metabolic
syndrome (aged 25–75 years) 8 weeks
↓ LDL-C, ↓non-HDL-C,
↓ TC, ↓ TG, ↓ Lp(a),
↑ HDL-C
compared with the placebo
sdLDL Panahi et al. 2014 [163]
1 g/day of curcuminoids (500 mg
C3Complex®+ 5 mg bioperine®Sami Labs





30 obese subjects (mean BMI
33.95 ± 3.81) 30 days
BMI and weight compared
with the placebo Esmaily et al. 2015 [186]
50 mg/day of curcumin
(250 mgCurcuWIN) or 200 mg/day of





59 healthy subjects aged
19–29 years 8 weeks
200 mg/ day of curcumin: ↑
endothelial function compared
with placebo
Oliver et al. 2016 [237]
↑—increased; ↓—decreased; ALT—alanine aminotransferase; AST—aspartate aminotransferase; BDNF—brain-derived neurotrophic factor; BMI—Body Mass Index; BUN—urea
nitrogen; CHD—coronary heart disease; CRP—C reactive protein; EGF—epidermal growth factor; ET-1—endothelin-1; FBFACh—forearm blood flow to brachial artery infusion of
acetylcholine; FFAs—free fatty acids; FMD—flow-mediated dilation; GPx—glutathione peroxidase; HbA1c—glycated haemoglobin; HDL- C—high-density lipoprotein cholesterol;
HOMA-IR—homeostasis model assessment insulin resistance; LDL-C—low-density lipoprotein cholesterol; Lp(a)—lipoprotein a; LPL—lipoprotein lipase; LPS—lipopolysaccharides;
MDA—Malondialdehyde; MCP-1—monocyte chemoattractant protein 1; NAFLD—non-alcoholic fatty liver disease; Nrf2—nuclear factor erythroid 2–related factor 2; NQO1—NAD(P)H:
quinone oxidoreductase; OGTT—oral glucose tolerance test; PWV—pulse wave velocity; QUICKI—quantitative insulin sensitivity check index; SBP—systolic blood pressure; sdLDL—small
dense low density lipoprotein; SOD—superoxide dismutase; TBARS—thiobarbituric acid reactive substances; TC—total cholesterol; TG—triglyceride; TGF-β—transforming growth factor
beta; T2DM—type 2 diabetes mellitus; TNF-α—tumor necrosis factor-alpha; VLDL—very low-density lipoprotein; VEGF—vascular endothelial growth factor.
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Early growth response-1 gene product (Egr-1) is a pathophysiological transcription factor which
induces the activity of plasminogen activator inhibitor type-1 (PAI-1). Elevated PAI-1 is related to
increased insulin resistance. Curcumin (0–40 µm/L) downregulated Egr-1 protein in HUVECs [235].
Reduced NO bioavailability (or reduced NO synthesis) is associated with endothelial
dysfunction [242]. Studies [243–245] showed that curcumin upregulated eNOS to improve endothelial
dysfunction in HUVECs when oxidative stress is induced by H2O2 [244] in 2K-1C hypertensive
rats [243] and in A10 vascular smooth muscle cells [245].
Curcumin has shown cardioprotective effects [246,247]. Curcumin treatment (150 mg/kg or 100 µm/L)
of diabetic rat hearts decreased oxidative DNA and protein damage by decreasing levels of endothelial nitric
oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) via reduced NF-kB and AP-11 in both
diabetic rat hearts and in microvascular endothelial cells induced by high glucose. [246]. A vasoconstrictor,
ET-1 levels increased with curcumin treatment in diabetic rat hearts and microvascular endothelial cells but
ET-1 levels in the kidneys and the retina decreased, indicating that curcumin acts differently on organs [246].
Curcumin treatment (5, 10 and 30 µm/L) inhibited inflammatory cytokines (MCP-1, TNF-α,
toll-like receptors (TLRs) and iNOS) and NO generation in vascular smooth muscle cells of rats
treated with LPS through the downregulation of TLR4-MAPK/NF-kB pathways related with
NADPH-mediated intracellular ROS generation [248].
3.8. Neurodegenerative Diseases
Diabetes mellitus enhances the risk of dementia. The impairments in glucose metabolism, insulin
signalling, insulin sensitivity and lipid metabolism, as well as increases in inflammation and oxidative stress
in central nerve and peripheral system, contribute to the risk of Alzheimer’s disease (AD) [249–252].
The etiology of AD includes accumulation of fibrillar amyloid-β (Aβ) peptides (amyloid plaques),
decreased Aβ degradation enzymes, Aβ oligomer-promoted synaptic dysfunction, neurotoxic mediators
from glial cells, apoE4 (lipid transport protein)-enhanced Aβ deposits, impaired mitochondrial function,
mis-localised tau protein from axons to neuronal soma and dendrites, increased neurofibrillary
tangles (NFTs—comprised of hyperphosphorylated tau) formation, self-assembled α-synuclein, vascular
abnormalities, impaired supply of nutrients, impaired metabolic by-product removals, as well as activated
glial cells [252]. Loss of neurons in certain brain areas such as pyramidal cells in lamina II of the entorhinal
cortex and in the CA1 region of the hippocampus are responsible for early AD pathology [253,254].
Moreover, the accumulation of advanced glycation end products (AGEs) and the receptor for
advanced glycation end products (RAGE) are associated with the T2DM, CVD, degenerative disease
and ageing [255–258]. The increased AGE binding to microglia, neurons and vascular endothelia cells
stimulates inflammatory actions and Aβ influx, which in turn leads to neuronal disfunction, cognitive
decline and brain damage [259,260].
Aβ oligomers in cultured hippocampal neurons lead to phosphorylation of tau and inhibition of
IRS-1 (Ser616) through the activation of c-Jun N-terminal kinase signalling, while curcumin treatment
of triple transgenic -AD mice on a high-fat diet showed reductions in phosphorylated JNK, IRS-1,
and tau in their brain [261].
Islet amyloid polypeptide (IAPP) or amylin is a hormone consisting of 37 amino acid residues
which is co-released with insulin from pancreatic β cells [262]. The accumulation of amyloid as
a consequence of the IAPP misfolding is associated with T2DM, AD and Parkinson’s disease [263,264].
Curcumin inhibited the self-assembly of IAPP [265,266].
In the hippocampal CA1 area of the brain of AD mice (PS1dE9 double transgenic mice model),
curcumin upregulated the expressions of GLUT1 and GLUT3 indicating an improvement in cerebral
glucose uptake. Curcumin also stimulated insulin-like growth factor (IGF)-1R, IRS-2, phosphoinositide
3-kinase (PI3K), p-PI3K, Akt and p-Akt protein, and suppressed IR and IRS-1 which implicates the
improvement in insulin signalling pathways [267]. In addition, curcumin enhanced spatial memory
and learning as assessed by the water maze behaviour test [268]. Aβ-derived diffusible ligands
(ADDLs) are known to dysfunction insulin signalling [269–271] and act as neurotoxins [272] in AD.
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Curcumin treatment showed decreases in Aβ40, Aβ42, ADDLs and γ-secretase [presenilin (PS2)]
expression, as well as increases in Aβ degradation enzymes such as insulin-degrading enzymes and
neprilysin in the hippocampus CA1 region. The changes in these molecules are related with improved
behaviour functions [268].
A recent RCT indicated that curcumin could reduce amyloid and tau accumulation in a certain brain
region leading to the improvement memory and attention. Non-demented adults (aged 51–84 years; n = 21)
who ingested curcumin (Theracurmin® containing 90 mg of curcumin twice daily) for 18 months showed the
enhanced memory and attention compared with a placebo. Amyloid and tau accumulation on brain were
assessed by 2-(1-[71] ethylidene)malononitrile positron emission tomography (FDDNP-PET). Curcumin
significantly lowered FDDNP binding in the amygdala (ES = −0.41, p = 0.04) compared with a placebo
(ES = 0.08, p = 0.6; between-group: ES = 0.48, p = 0.07) [71].
An AD brain shows an overexpression of PI3K/Akt/mTOR signalling, which is associated
with insulin resistance and the pathology of Aβ and tau [273,274]. Curcumin decreased cognitive
impairment as assessed by Morris water maze test, inhibited Aβ generation, and suppressed PI3K,
phosphorylated Akt and mammalian target of rapamycin (mTOR—Akt regulating cell growth,
proliferation, survival, angiogenesis, as well as autophagy [275]) leading to stimulated autophagy,
in APP/PS1 double transgenic mice (an AD mice model) [276].
The modification of synapse structure and function is associated with the development of AD.
The decreases in synapse-related proteins, including PSD95 and Shank1, contribute to the pathology of
AD. Curcumin treatment improved the quantity and structure of the synapse by facilitating the
PSD95 and Shank1 in the hippocampal CA1 regions of the APPswe/PS1dE9 double transgenic
mice [277]. Curcumin treatment improved synaptic plasticity and neurogenesis resulting in improved
memory function [278–280].
Brain-derived neurotrophic factor (BDNF) is a protein which stimulates neurogenesis, synaptic
plasticity and memory in hippocampus and frontal cortex (FC) [281]. Decreased levels of BDNF are
reported in obese and diabetic conditions [282–285]. Franco-Robles et al. 2014 [142] conducted both
animal and human studies to investigate effects of curcumin on BDNF levels in the hippocampus and
FC of diabetic db/db mice and in sera of obese subjects. Compared to baseline, curcumin treatment
(50 mg/kg daily) for 8 weeks normalised BDNF levels in the hippocampus and FC of diabetic db/db
mice. However, nondiabetic obese human subjects who consumed curcumin (500 and 750 mg/day)
for 12 weeks did not have altered BDNF levels. Curcumin (500 mg) significantly decreased LDL-C
in weeks 2 and 12. Curcumin (500 mg) in weeks 6 and 12 significantly decreased TBARS and oxLDL.
Curcumin (500 mg and 750 mg) significantly lowered protein carbonyls levels in week 2, 6 and 12.
Curcumin (500 mg and 750 mg) did not alter body weight, BMI, fat, glucose, TC, TG, HDL-C, VLDL
and uric acid during the study period [142].
Membrane integrity is important to mainting the normal function of mitochondria and synapse
in brain [286,287]. Curcumin facilitated the DHA biosynthesis in liver and DHA accumulation in the
brain indicating that curcumin (1–10, 20, or 40 µm/L) can improve cell membrane integrity in the brain,
consequently leading to the improvement of neurodegenerative disease by enhancing mitochondria
and synaptic function [288,289].
Inflammation is a key player in the development of neurodegenerative diseases [290]. Microglial cells are
resident macrophages that play a crucial role in innate immune regulation and brain homeostasis [291–293].
COXs participate in PGs formation [294]. The expression of COXs occurs when microglial cells and astrocytes
are stimulated by inflammation [295]. Curcumin treatment (4–20 µm/L) inhibited LPS-activated COX-2
gene expression and pro-inflammatory cytokines through the suppression of NF-kB and Activator Protein 1
(AP-1) in BV2 microglial cell [296,297]. Curcumin treatment (20 µm/L) suppressed migration of microglia in
LPS-activated BV-2 cells with the inhibition of IL-4, PPAR-α, TLR 2, Prostaglandin-endoperoxide synthase 2
and NO synthase 2, indicating an anti-inflammatory and neuroprotective effects of curcumin [298].
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4. Conclusions
A summary of possible mechanisms of curcumin on glucose homeostasis, lipid metabolism,
oxidative stress, inflammation and endothelial function is shown in Figure 2.
In conclusion, based on high-dose animal and in vitro studies, curcumin appears to be a promising
therapeutic agent to decrease the risk of T2DM, CVD and neurodegenerative disease by improving
glucose homeostasis, lipid metabolism, endothelial function and insulin signalling, and by inhibiting
Aβ aggregation. These favourable effects of curcumin could be attributable to potent anti-oxidant and
anti-inflammatory actions.
To avoid misinterpretation of results from in vitro studies, it should be noted that cells used
in most of the in vitro studies were exposed to very high level of curcumin, i.e., 10 to 100 times
greater than the circulating dose measured in plasma after consumption of curcumin supplements or
curcumin-rich meal.
There is variability in curcumin metabolism between humans and animals. Thus, the results of
in vitro and animal studies cannot be directly related to human physiology. The formula to convert
animal doses into human doses for the determination of the equivalents of animal doses in human
doses is as follows: human effective dose (mg/kg body weight) = animal dose (mg/kg) X animal
km/human km. The correction factor (km) is calculated by dividing the average body weight (kg)
of species to its body surface area (m2) [299]. Frequently, animal doses are well beyond normal
human doses.
Curcumin is metabolised to curcumin glucuronide or curcumin sulphate by glucuronidase and
sulfatase, respectively. The predominant curcumin glucuronides metabolites are terahydrocurcumin
(THC) and hexahydrocurcumin (HHC). The minor curcumin metabolites are dihydroferulic acid and
ferulic acid. These water-soluble metabolites are excreted through the urine [30]. Ninety-nine percent
of plasma curcumin is glucuronide-conjugates. The maximum plasma concentrations of curcuminoid
conjugates were observed within 1 h of oral administration in humans [25]. It is unclear whether
curcumin metabolites are more or less bioactive than native curcumin [30,300–302].
Human studies at present are relatively unconvincing. So far, new curcumin formulations have been
tested to assess an increase in bioavailability and efficacy in animal studies. A few clinical interventions
have been conducted to see if the increased bioavailability with the new curcumin formulations is associated
with cardiometabolic benefit, but no direct comparisons have been made with standard formulations.
Int. J. Environ. Res. Public Health 2018, 15, 2093 19 of 34
Figure 2. The summary of potential mechanisms linking curcumin metabolites to improved glucose, lipid metabolism, antioxidative action, anti-inflammatory action
and endothelial function. Refer to the text for more details. ↑—increase; ↓—decrease; ABCA1—ATP-binding cassette A1; ACAT—acyl-CoA cholesterol acyltransferase;
Akt—serine/threonine kinase; AMPK—5′ adenosine monophosphate–activated protein kinase; ARE—antioxidant-responsive element; β3AR—β3-adrenergic receptor;
CAT—catalase; ChREBP—carbohydrate response element-binding protein; CML—Nε-(carboxymethyl) lysine; COX-2—cyclo-oxygenase 2; CRP—C–reactive protein;
CYP7A—cholesterol 7α-hydroxylase; Egr-1—early growth response-1 gene product; eNOS—endothelial nitric oxide synthase; ER—endoplasmic reticulum; ERK1/2—extracellular
signal-regulated protein kinases 1 and 2; FAS—fatty acid synthase; FOXO1—forkhead box protein O1; GCLM—γ-glutamyl-cysteine ligase; G6Pase—glucose–6–phosphatase;
GK—glucokinase; GLUT4—glucose transporter 4; GPx—glutathione peroxidase; GSK-3β—glycogen synthase kinase-3 beta; GST—glutathione-S-transferase; HATs—histone
acetylases; HMG-CoA reductase—3-Hydroxy-3-methylglutaryl-coenzyme A reductase; HO-1—heme oxygenase1; IL—interleukin; iNOS—inducible nitric oxide
synthase; IRS1—insulin receptor substrate-1; JNK—Jun NH2-terminal kinase; LKB1—serine–threonine liver kinase B1; LOX-1—lectin-like oxidised LDL receptor;
LPL—lipoprotein lipase; LPS—lipopolysaccharides; LXRα—liver X receptor alpha; MAPK—mitogen-activated protein kinase; MCP-1—monocyte chemoattractant protein
1; MDA—malondialdehyde; MGO—methylglyoxal; NF-kB—nuclear factor kappa B; mTOR—mammalian target of rapamycin; Nrf2—nuclear factor erythroid 2–related
factor 2; NQO1—NAD(P)H dehydrogenase [quinone] 1; NPC1L1—Niemann-Pick C1 Like 1; PAI-1—plasminogen activator inhibitor type -1; PARP-1—poly ADP-ribose
polymerase-1; PDE—phosphodiesterase; PEPCK—phosphoenolpyruvate carboxykinase; PGE2—prostaglandin E2; PI3K—phosphoinositide 3–kinase; PKC-Bii—protein kinase C;
PPAR—peroxisome proliferator-activated receptor; ROS—reactive oxygen species; SCD-1—stearoyl-coenzyme A desaturase 1; SOD—superoxide dismutase; SREBP1c—sterol
regulatory element-binding protein 1c; TBARS—thiobarbituric acid reactive substances; TGF-β—transforming growth factor beta; TLR4—toll-like receptors 4; TNFα—tumor
necrosis factor α; UCP1—uncoupling protein 1; VEGF—vascular endothelial growth factor.
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